Subsequent study identified that IDH1/IDH2 mutations were more prevalent in WHO grade II/III glioma than GBM, and patients occurred IDH gene mutations share a better outcome than those of wildtype IDH genes.32 The gene discussed is IDH2; the disease is central nervous system cancer.